Brief: CytRx says partial clinical hold affecting aldoxorubicin clinical trials

LadRx

18/11/2014 11:00

Nov 18 (Reuters) - CytRx Corp  CYTR.O : 
 * Announces partial clinical hold affecting aldoxorubicin clinical trials 
 * Says company expects trial timelines to remain materially unchanged 
 * Says all currently enrolled patients can continue receiving aldoxorubicin 
   therapy or comparator drugs 
 * Says one inclusion/exclusion criteria to be amended for new trial patients to 
   add additional safety measure 
 * Says CytRx currently believes that the partial hold issue will be 
   expeditiously resolved 
 * Says has received notice from FDA that its clinical trials for aldoxorubicin 
   have been placed on partial clinical hold 
 * Says CytRx currently believes that enrollment rates and timelines for its 
   ongoing trials will remain materially unchanged 
 * Partial clinical hold is due to the reported death of patient with 
   advanced-stage cancer who did not qualify to participate in any of trials 
 * Remains committed to completing enrollment of its ongoing pivotal global 
   phase 3 trial in second-line soft tissue sarcoma by the end of 2015 
 * Currently expects to announce preliminary results from ongoing phase 2 
   clinical trial of aldoxorubicin in kaposi's sarcoma in Q2 2015 
 * Expects preliminary results from ongoing phase 2 clinical trial of 
   aldoxorubicin in glioblastoma multiforme in the first half of 2015 
 * Remains committed to completing enrollment of ongoing pivotal global phase 3 
   trial in second-line soft tissue sarcoma by end of 2015 
 
 * Source text for Eikon  ID:nPn2YrHnp  
 
 * Further company coverage  CYTR.O  
 
 ((Bangalore Newsroom; +1 646 223 8780))